HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
HUTCHMED (China) LimitedNASDAQ: HCM
Investing Cash Flow · Q2 FY2025 · quarter ended Jun 2025
Investing cash flow turns positive
Q2 FY2025 investing cash flow was $8.8M, compared with -$2.72M a year earlier. Trailing-twelve-month investing cash flow was -$73.03M.
Context
- Investing cash flow amounted to 5.4% of revenue in FY2025, down 9.9 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near $8.8M or moves back toward the trailing-twelve-month quarterly average of -$18.26M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (29.49M) USD
- Year-over-year change
- +69.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.49M) | +69.3% |
| FY2024 | 2024-12-31 | (96.06M) | +67.0% |
| FY2023 | 2023-12-31 | (291.14M) | -198.2% |
| FY2022 | 2022-12-31 | 296.59M | +196.8% |
| FY2021 | 2021-12-31 | (306.32M) | — |
Investing Cash Flow vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -476.7% is the lowest of 9, against a peer median of +217.4%.
- Investing cash flow amounts to 12.1% of revenue for HCM, versus a peer median of 43.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.64B USD | — | +26.9% | 136.5% | |
| LTM Jun 2026 | €1.03B EUR | -158.3% | +306.5% | 39.1% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥1B CNY | +176.2% | +37.5% | 179.1% |
| LTM Sep 2026 | $226.82M USD | +1455.9% | — | 16.7% | |
| LTM Jun 2026 | $224.83M USD | +23174.4% | +9.3% | 3.9% | |
| LTM Mar 2026 | $109.11M USD | +258.7% | — | 48.4% | |
| LTM Jul 2026 | $93.01M USD | +840.9% | — | 3.8% | |
| LTM Jun 2025 | $73.03M USD | -476.7% | — | 12.1% | |
| LTM Jun 2026 | $63M USD | -67.0% | — | 53.8% | |
| LTM Jun 2026 | $39.05M USD | -28.3% | -9.8% | 8.7% | |
| LTM Jun 2024 | $4.81M USD | — | — | 74.1% | |
| Peer median (excluding HCM) | — | +217.4% | +26.9% | 43.7% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.04M) | (360.39M) | 100.78M | 37.73M | 458.12M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| Deferred Income Tax | (115.14M) | 0 | (102.76M) | 0 | 0 |
| Stock-Based Compensation | 41.99M | 30.59M | 36.6M | 21.61M | 15.29M |
| Change in Working Capital | 32.46M | 58.7M | 71.15M | (62.17M) | (61.02M) |
| Accounts Receivables | (35.63M) | (14.45M) | (21.34M) | (41.57M) | 28.94M |
| Inventory | (16M) | (21.21M) | 4.14M | (772K) | 9.57M |
| Accounts Payables | 9.57M | 29.94M | (32.54M) | 0 | 3.02M |
| Other Working Capital | 74.53M | 64.04M | 120.89M | (19.82M) | (102.55M) |
| Other Non-Cash Items | (3.68M) | (6.17M) | 105.28M | (9.01M) | (490.56M) |
| Operating Cash Flow | (204.22M) | (268.6M) | 219.26M | 497K | (64.83M) |
| Capital Expenditures | (16.76M) | (36.66M) | (32.61M) | (17.93M) | (14.19M) |
| Acquisitions (Net) | 159.12M | 324K | (2.99M) | 0 | 28.07K |
| Purchases of Investments | (1.37B) | (1.2B) | (1.63B) | (1.85B) | (2.75B) |
| Sales of Investments | 921.36M | 1.52B | 1.37B | 1.77B | 2.74B |
| Other Investing Activities | 930K | 16.49M | 29.5M | 1.28M | 0 |
| Investing Cash Flow | (306.32M) | 296.59M | (291.14M) | (96.06M) | (29.49M) |
| Debt Repayment | (579.77K) | (9.17M) | 61.71M | 5.61M | 6.27M |
| Common Stock Issued | 717.32M | 174K | 5.09M | 790K | 1.58M |
| Common Stock Repurchased | (27.31M) | (48.08M) | (9.07M) | (36.06M) | 0 |
| Dividends Paid | (99.74M) | (87.44M) | 0 | 0 | 0 |
| Other Financing Activities | 60.34M | 61.75M | (9.07M) | (1M) | 0 |
| Financing Cash Flow | 650.03M | (82.76M) | 48.66M | (30.67M) | 7.86M |
| Effect of Forex Changes | 2.43M | (9.49M) | (6.47M) | (3.4M) | 3.83M |
| Net Change in Cash | 141.91M | (64.26M) | (29.69M) | (129.63M) | (82.63M) |
| Free Cash Flow | (220.98M) | (305.26M) | 186.65M | (17.44M) | (79.01M) |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.